Core Viewpoint - Bioventus Inc. reported a decline in revenue for the first quarter of 2025, primarily due to the divestiture of its Advanced Rehabilitation Business, but achieved organic revenue growth across all business segments, indicating resilience in its strategic execution despite macroeconomic challenges [2][6]. Financial Performance - Worldwide revenue for Q1 2025 was $123.9 million, a decrease of 4.3% from $129.5 million in the same period last year, largely impacted by the divestiture [2][5]. - Organic revenue increased by 5.0%, reflecting positive growth across all three business segments [2][6]. - The net loss attributable to Bioventus Inc. was $2.6 million, an improvement from a net loss of $4.9 million in the prior-year period [3][4]. - Adjusted EBITDA for the quarter was $19.2 million, down from $22.6 million in the previous year, primarily due to the divestiture and planned growth investments [3][6]. Revenue Breakdown by Business - U.S. revenue from Pain Treatments was $52.7 million, up 4.0% year-over-year, while Surgical Solutions revenue increased by 6.5% to $40.8 million [5][8]. - Restorative Therapies revenue fell by 32.9% to $17.0 million, significantly affected by the divestiture of the Advanced Rehabilitation Business [5][9]. - International revenue totaled $13.4 million, a decline of 12.0%, with Pain Treatments and Surgical Solutions showing modest growth, while Restorative Therapies revenue dropped by 47.1% [5][9]. Strategic Developments - The company reiterated its financial guidance for 2025, expecting net sales between $560 million and $570 million, reflecting organic growth of approximately 6.1% to 8.0% when accounting for the divestiture [10][13]. - Adjusted EBITDA guidance for 2025 is set between $112 million and $116 million, indicating a potential increase in Adjusted EBITDA margin compared to 2024 [10][13]. - Non-GAAP EPS is projected to be between $0.64 and $0.68, representing a growth of 30.6% to 38.8% [10][13].

Core Insights - Clorox reported $1.67 billion in revenue for the quarter ended March 2025, reflecting an 8.1% year-over-year decline and an EPS of $1.45, down from $1.71 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate by 2.67%, while the EPS also missed the consensus estimate by 7.64% [1] Financial Performance Metrics - Organic Revenue Growth in Health and Wellness was 3%, surpassing the average estimate of -1.9% [4] - Organic Revenue Growth in International was 2%, below the average estimate of 6% [4] - Organic Revenue Growth in Lifestyle was -3%, compared to the average estimate of 0.3% [4] - Organic Revenue Growth in Household was -11%, significantly lower than the average estimate of -1.5% [4] - Overall Organic Sales Growth was -2%, missing the average estimate of 1.2% [4] Revenue Breakdown - Net Revenue for Health and Wellness was $630 million, exceeding the average estimate of $597.23 million, representing a 3.5% year-over-year increase [4] - Net Revenue for International was $263 million, slightly above the average estimate of $258.40 million, but reflecting a 15.2% year-over-year decline [4] - Net Revenue for Lifestyle was $306 million, below the average estimate of $314.14 million, indicating a 2.9% year-over-year decrease [4] - Net Revenue for Household was $469 million, significantly lower than the average estimate of $515.48 million, showing a 10.8% year-over-year decline [4] Income Before Taxes - Income before income taxes for Health and Wellness was $169 million, slightly below the average estimate of $176.17 million [4] - Income before income taxes for Corporate and Other was -$55 million, better than the average estimate of -$68.49 million [4] - Income before income taxes for International was $31 million, exceeding the average estimate of $27.86 million [4] Stock Performance - Clorox shares have returned -3.3% over the past month, while the Zacks S&P 500 composite has increased by 0.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Fourth Quarter and Full Year 2024 Earnings March 4, 2025 Forward-looking statements and non-GAAP financial measures Forward-Looking Statements This presentation and today's webcast include "forward-looking statements" within the meaning of U.S. federal securities laws. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probabil ...